XTX Topco Ltd Invests $615,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

XTX Topco Ltd acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 14,861 shares of the company’s stock, valued at approximately $615,000.

Several other institutional investors have also modified their holdings of the business. Jones Financial Companies Lllp raised its stake in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after acquiring an additional 357 shares in the last quarter. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $69,000. AlphaQuest LLC lifted its stake in Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after purchasing an additional 1,658 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock worth $172,000 after buying an additional 312 shares in the last quarter. Finally, Avanza Fonder AB acquired a new position in Mirum Pharmaceuticals in the fourth quarter worth approximately $189,000.

Mirum Pharmaceuticals Stock Up 0.9 %

MIRM opened at $39.10 on Friday. The company has a market capitalization of $1.92 billion, a P/E ratio of -19.36 and a beta of 1.00. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm’s fifty day moving average price is $45.23 and its two-hundred day moving average price is $43.96. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. HC Wainwright upped their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $58.20.

Insider Activity at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 7,879 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the completion of the sale, the chief operating officer now directly owns 18,672 shares in the company, valued at approximately $825,489.12. This trade represents a 29.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Christopher Peetz sold 6,837 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $327,629.04. Following the completion of the transaction, the chief executive officer now directly owns 125,022 shares of the company’s stock, valued at approximately $5,991,054.24. This represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,473 shares of company stock valued at $5,249,134 in the last 90 days. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.